Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
~50kDa (SDS-PAGE; reducing conditions)~100kDa (SDS-PAGE; non-reducing conditions)~300kDa (SDS-PAGE; native conditions; multimerizes and forms hexamers)
The receptor-binding domain of human BAFF (aa 136-285) is fused at the N-terminus to the Fc portion of human IgG1.
Human IgG1 Fc
Greater than 95% by SDS-PAGE
Rescues the production of mature follicular and marginal zone B cells. - in vitro: Addition of 1-100 ng/ml of Fc-BAFF induces B cell survival in a dose-dependent manner. - in vivo: Fc-BAFF treatment rescues mature B cell development in BAFF deficient mice
Less than 0.01 EU/µg protein (determined by LAL method).
Lyophilized from PBS.
Reconstitute with 100 µl sterile water.
Store lyophilized at -20°C for at least 6 months. Once reconstituted store at +4°C for immediate use.
Members in the TNF superfamily regulate immune responses and induce apoptosis. A novel member in the TNF family was recently identified by several groups and designated BAFF (for B cell Activating Factor belonging to the TNF Family), BLyS (for B Lymphocyte Stimulator), TALL-1 (for TNF- and ApoL-related Leukocyte-expressed Ligand), and THANK (for TNF Homologue that Activate Apoptosis, NF-kB and c-jun N-terminal Kinase).
Restoration of the splenic T and B cell architecture in Fc-BAFF injected BAFFdeficient mice. BAFF deficient mice were injected at day 0 with 100mg BAFF (human):Fc (human) (AG-40B-0120) intravenously and at day 14 with 50mg BAFF (human):Fc (human) intraperitoneal. At day 21, injected BAFFdeficient mice were sacrificed together with WT and control BAFFdeficient mice and splenic T and B cell architecture was analyzed by fluorescence microscopy on cryosections. A, Spleen sections of WT (left picture), BAFF deficient (middle picture) or injected BAFFdeficient mice (right picture) were stained for IgM (red) and CD90 (green). (B) Spleen sections of the same mice were stained for IgM (green) and MOMA (red).